Innovent Biologics Inc (HKSE:01801) Share Price

Company Profile

Business description
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has 12 commercialized oncology products and three commercialized nononcology products as of March 2025. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Contact
168 Dongping Street
Suzhou Industrial Park
Jiangsu Province
Suzhou215123
CHN
T: +86 51269566088
https://www.innoventbio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
6,190

Recommended

This share is trading at the lowest price to fair value of the 14 companies on the list.

Angus Hewitt, CFA | 05 January 2026

Despite a surging share price a weakening competitive position causes a reassessment of our view.

Shane Ponraj, CFA | 05 January 2026

We believe these companies’ strong ESG management practices give them a long-term advantage.

Margaret Giles | 04 January 2026

Index	Last price	Change	% Change
All Ordinaries	8,996.90	78.80	-0.87%
CAC 40	8,237.78	26.28	0.32%
DAX 40	24,936.33	67.64	0.27%
Dow JONES (US)	49,142.94	165.76	0.34%
FTSE 100	10,122.57	118.00	1.18%
HKSE	26,710.45	363.21	1.38%
NASDAQ	23,504.05	108.23	0.46%
Nikkei 225	52,518.08	685.28	1.32%
NZX 50 Index	13,663.58	76.35	0.56%
S&P 500	6,929.87	27.82	0.40%
S&P/ASX 200	8,682.80	88.50	-1.01%
SSE Composite Index	4,083.67	60.25	1.50%